Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: science (2)

Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler Korman
investorpress clippingsvideoscience
Bloomberg TV: Jane King interviews co-founder and VP of Research, Dr. Tyler KormanApril 15, 2025
BioClick - an enzyme engineering game-changer
press releaseinvestorscience
BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grantApril 10, 2025
Chemical Engineering: Enzyme engineering breaks out of the cell
press clippingsscience
Chemical Engineering: Enzyme engineering breaks out of the cellApril 1, 2025
NREL
biofuelinvestorscienceARCHIVE
ARCHIVE: NREL (DoE) working with Invizyne in their 'Advancing Clean Tech to Energize the Future' project - a fireside chatAugust 2, 2024
ARCHIVE: The story of eXoZymes: Interview with Tyler Korman and Paul Opgenorth
videoscienceARCHIVE
ARCHIVE: The story of eXoZymes: Interview with Tyler Korman and Paul OpgenorthMay 22, 2024
ARCHIVE: A bio-inspired cell-free system for cannabinoid production from inexpensive inputs
sciencepublicationARCHIVE
ARCHIVE: A bio-inspired cell-free system for cannabinoid production from inexpensive inputsAugust 24, 2020
ARCHIVE: Synthetic Biochemistry: The Bio-inspired Cell-Free Approach to Commodity Chemical Production
sciencepublicationARCHIVE
ARCHIVE: Synthetic Biochemistry: The Bio-inspired Cell-Free Approach to Commodity Chemical ProductionJuly 1, 2020
ARCHIVE: A cell-free platform for the prenylation of natural products and application to cannabinoid production
sciencepublicationARCHIVE
ARCHIVE: A cell-free platform for the prenylation of natural products and application to cannabinoid productionFebruary 4, 2019
ARCHIVE: A molecular rheostat maintains ATP levels to drive a synthetic biochemistry system
sciencepublicationARCHIVE
ARCHIVE: A molecular rheostat maintains ATP levels to drive a synthetic biochemistry systemJuly 3, 2017
ARCHIVE: A synthetic biochemistry platform for cell free production of monoterpenes from glucose
sciencepublicationARCHIVE
ARCHIVE: A synthetic biochemistry platform for cell free production of monoterpenes from glucoseMay 24, 2017
Previous page
Page 2 of 3
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark